Fresenius Kabi v. Accord Healthcare: Levothyroxine Injection Patent Action Voluntarily Dismissed
Fresenius Kabi USA, LLC filed suit against Accord Healthcare Inc. in the District of New Jersey asserting two patents covering levothyroxine sodium injection (100 mcg/mL). The action was voluntarily dismissed under Rule 41(a)(1)(A)(i) after 150 days, with the public record silent on whether any settlement terms accompanied the exit.
Early voluntary exit in a pharma formulation patent dispute
On 26 April 2024, Fresenius Kabi USA, LLC filed a patent infringement action against Accord Healthcare Inc. in the United States District Court for the District of New Jersey, Case No. 2:24-cv-05674. The complaint asserted two patents — US11135190B2 and US10398669B2 — both directed at levothyroxine sodium injection formulations, specifically the 100 mcg/mL product supplied in 1 mL, 2 mL, and 5 mL presentations. Plaintiff was represented by ArentFox Schiff LLP.
The case closed on 23 September 2024, just 150 days after filing, through a voluntary dismissal filed by Fresenius Kabi under Federal Rule of Civil Procedure 41(a)(1)(A)(i). This procedural mechanism allows a plaintiff to dismiss without a court order at any time before the opposing party serves an answer or a motion for summary judgment. The public record does not specify whether the dismissal was with or without prejudice, nor does it disclose whether a settlement agreement was reached.
A resolution at 150 days — before any substantive motion practice or Markman hearing — suggests the dispute may have been resolved through negotiation or that the plaintiff reassessed its enforcement strategy early. ANDA-related levothyroxine litigation frequently involves parallel regulatory dynamics that can shift litigation calculus quickly. What drove Fresenius Kabi’s decision to exit at this stage, and on what terms, remains unknown from the publicly available record.
Filing to Voluntary dismissal in 150 days
150-day duration — resolved before any substantive court ruling
Voluntarily dismissed: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i): plaintiff’s unilateral right to exit
Federal Rule of Civil Procedure 41(a)(1)(A)(i) permits a plaintiff to dismiss an action without a court order before the defendant has served an answer or a motion for summary judgment. The dismissal is self-executing — it takes effect upon filing. Critically, the rule does not require the plaintiff to state whether the dismissal is with or without prejudice, leaving that question open unless the notice specifies otherwise.
Procedural dismissalWith or without prejudice? The public record is silent
A dismissal ‘with prejudice’ bars Fresenius Kabi from re-filing the same claims against Accord on these patents. A dismissal ‘without prejudice’ preserves that right. The filed notice invokes Rule 41(a)(1)(A)(i) without specifying either. Under the Federal Rules, a first voluntary dismissal is generally treated as without prejudice by default unless stated otherwise — but practitioners should verify the actual docket entry before drawing enforcement conclusions.
Prejudice status unconfirmedFresenius Kabi retains its patents but litigation posture is uncertain
US11135190B2 and US10398669B2 remain in force and were not adjudicated on the merits. Fresenius Kabi may pursue future enforcement against Accord or other ANDA filers depending on the dismissal’s prejudice status and any private terms. The early exit avoids adverse claim construction or validity rulings, preserving optionality — but also means no injunctive protection was confirmed.
Patents unlitigated on meritsAccord faces no court-imposed bar — but uncertainty persists
Accord Healthcare Inc. obtained dismissal of the action without any adverse judgment, meaning no injunction or damages were ordered. If the dismissal is without prejudice, Fresenius Kabi could reinitiate suit, particularly if Accord’s levothyroxine sodium injection product reaches or expands on the market. The absence of a merits ruling leaves the validity and infringement questions entirely open for future proceedings.
No adverse judgment recordedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Fresenius Kabi | Individual | Pharmaceutical formulation company — holder of US11135190B2 and US10398669B2Search in Eureka ↗ |
| Defendant | Accord Healthcare, Ltd. | Company | Generic pharmaceutical manufacturer targeted over levothyroxine sodium injection ANDASearch in Eureka ↗ |
| Plaintiff counsel | Ahmed Muhammad Tan Riaz | Attorney | Counsel for Fresenius KabiSearch in Eureka ↗ |
| Plaintiff law firm | ArentFox Schiff LLP | Law Firm | Representing Fresenius KabiSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) and names the defendant as ‘Accord Healthcare Inc.’ — consistent with a unilateral plaintiff exit filed before any responsive pleading. The notice does not contain merits findings, claim construction, or validity determinations. Neither party’s legal position on infringement or the scope of US11135190B2 or US10398669B2 was adjudicated. The absence of prejudice language in the quoted text means the default Federal Rules treatment — typically without prejudice for a first voluntary dismissal — may apply, though practitioners should verify the complete docket filing.
US11135190B2 & US10398669B2 — Levothyroxine Sodium Injection Formulations
US11135190B2 (Application No. 16/511220) and US10398669B2 (Application No. 15/700258) both relate to levothyroxine sodium injection technology — a critical thyroid hormone replacement therapy administered intravenously in acute care settings. Levothyroxine sodium injection at 100 mcg/mL presents formulation challenges including stability, pH control, and excipient compatibility, areas where patent protection tends to concentrate in the specialty injectable segment.
For the levothyroxine sodium injection market, these two patents represent Fresenius Kabi’s core IP barrier against generic entry. The sequential application numbers suggest a continuation or divisional relationship, meaning the patents may share a common priority date while covering distinct claim sets — a structure designed to maximise coverage duration and breadth. Any generic or biosimilar manufacturer targeting this formulation space should conduct a full family and prosecution history review before filing an ANDA or launching a product.
Should you run an FTO analysis against US11135190B2 and US10398669B2?
Any pharmaceutical manufacturer, contract development and manufacturing organisation, or ANDA applicant developing levothyroxine sodium injection products at 100 mcg/mL concentration should treat these two Fresenius Kabi patents as active enforcement risk — regardless of this case’s voluntary dismissal. The absence of a merits ruling means neither patent has been held invalid or not infringed, and Fresenius Kabi retains the right to enforce against future entrants.
PatSnap Eureka’s FTO Search Agent enables R&D and regulatory teams to map claim scope across US11135190B2 and US10398669B2, identify continuation family members that may extend protection, and benchmark formulation design-arounds. Eureka’s AI-driven claim analysis surfaces the specific claim elements most relevant to your formulation approach, helping you prioritise clearance work before committing to manufacturing scale-up or ANDA submission.
Run a freedom-to-operate analysis on US11135190B2 to assess your product’s exposure
Run FTO in Eureka →Similar levothyroxine and injectable pharma patent cases in federal district courts
Cases involving injectable pharmaceutical formulation patents in the District of New Jersey and related Hatch-Waxman adjacent disputes over levothyroxine sodium products.
What this case signals for the injectable pharma patent IP landscape
Early voluntary dismissals in Hatch-Waxman adjacent cases often mask complex negotiation dynamics that never surface in the public record.
Pre-answer dismissals signal fast-moving ANDA negotiation dynamics
When a branded pharmaceutical company files and then voluntarily dismisses within 150 days — before any court ruling — it typically suggests either a licensing arrangement, a consent judgment, or a strategic reassessment tied to regulatory timelines. IP teams monitoring levothyroxine sodium injection freedom-to-operate should treat this outcome as inconclusive rather than a clear path to market.
Two-patent assertion strategy signals layered claim coverage
Fresenius Kabi’s simultaneous assertion of US11135190B2 and US10398669B2 — derived from separate application chains — suggests a deliberate layered enforcement strategy around the levothyroxine sodium injection formulation. Competitors and ANDA applicants should map both patents’ claim scope before assuming one patent’s expiry or lapse eliminates infringement risk.
Kabi v Accord — key questions answered
Fresenius Kabi asserted US11135190B2 (Application No. 16/511220) and US10398669B2 (Application No. 15/700258) against Accord Healthcare Inc. Both patents relate to levothyroxine sodium injection formulations, specifically the 100 mcg/mL product in 1 mL, 2 mL, and 5 mL presentations.
Fresenius Kabi filed a Rule 41(a)(1)(A)(i) voluntary dismissal on 23 September 2024, approximately 150 days after filing. The public record does not disclose the reason — possible explanations include a private settlement, a licensing arrangement, or a strategic reassessment. No merits rulings were issued before dismissal.
The publicly available dismissal notice does not specify whether it is with or without prejudice. Under the Federal Rules of Civil Procedure, a first voluntary dismissal under Rule 41(a)(1)(A)(i) is generally treated as without prejudice by default unless the notice states otherwise. Practitioners should review the full docket filing to confirm.
Yes. Neither patent was adjudicated on the merits — there was no claim construction, validity ruling, or infringement finding. Both US11135190B2 and US10398669B2 remain in force. Fresenius Kabi retains the right to assert them against Accord or other parties, subject to any undisclosed private terms from the dismissal.
Levothyroxine sodium injection is used for thyroid hormone replacement in patients who cannot take oral medication, making it a critical acute-care product. Patent protection over formulation, stability, and excipient technology creates significant barriers to generic entry. Fresenius Kabi’s two-patent strategy around this specific concentration and volume range suggests targeted coverage of its commercial product portfolio.
PatSnap Eureka searches patents and litigation data to answer instantly.